[SURVIVAL TIME AND ABILITY TO WORK IN HEMOBLASTOSES TREATED BY CHEMOTHERAPY].
D000970:Antineoplastic Agents; D001388:Aziridines; D035843:Biomedical Research; D003520:Cyclophosphamide; D040181:Genetic Diseases, X-Linked; D006689:Hodgkin Disease; D007938:Leukemia; D007943:Leukemia, Hairy Cell; D007945:Leukemia, Lymphoid; D007951:Leukemia, Myeloid; D008206:Lymphatic Diseases; D016403:Lymphoma, Large B-Cell, Diffuse; D008228:Lymphoma, Non-Hodgkin; D009369:Neoplasms / Q000532:radiotherapy*; D009588:Nitrogen Mustard Compounds; D010954:Plasmacytoma; D011379:Prognosis; D012509:Sarcoma; D016511:Severe Combined Immunodeficiency; D013223:Statistics as Topic; D013852:Thiotepa; D014265:Triethylenemelamine
D000970:Antineoplastic Agents; D001388:Aziridines; D009588:Nitrogen Mustard Compounds; D003520:Cyclophosphamide; D013852:Thiotepa; C026480:inproquone; D014265:Triethylenemelamine
ANTINEOPLASTIC AGENTS; BAYER E39; CLINICAL RESEARCH; CYCLOPHOSPHAMIDE; HODGKIN'S DISEASE; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC; LEUKEMIA, MYELOCYTIC; NEOPLASM RADIOTHERAPY; NITROGEN MUSTARD COMPOUNDS; PLASMACYTOMA; PROGNOSIS; RETICULOENDOTHELIOSIS; SARCOMA, RETICULUM CELL; STATISTICS; THIO-TEPA; TRIETHYLENE MELAMINE
UBERLEBENSZEIT UND LEISTUNGSFAEHIGKEIT BEI CHEMOTHERAPEUTISCH BEHANDELTEN HAEMOBLASTOSEN.